Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer

Small cell lung cancer (SCLC) is one of the most aggressive forms of cancer, with a 5-year survival <7%. A major barrier to progress is the absence of predictive biomarkers for chemotherapy and novel targeted agents such as PARP inhibitors. Using a high-throughput, integrated proteomic, transcrip...

Descripción completa

Detalles Bibliográficos
Autores principales: Stewart, C. Allison, Tong, Pan, Cardnell, Robert J., Sen, Triparna, Li, Lerong, Gay, Carl M., Masrorpour, Fatemah, Fan, You, Bara, Rasha O., Feng, Ying, Ru, Yuanbin, Fujimoto, Junya, Kundu, Samrat T., Post, Leonard E., Yu, Karen, Shen, Yuqiao, Glisson, Bonnie S., Wistuba, Ignacio, Heymach, John V., Gibbons, Don L., Wang, Jing, Byers, Lauren Averett
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438673/
https://www.ncbi.nlm.nih.gov/pubmed/28212573
http://dx.doi.org/10.18632/oncotarget.15338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438673/
https://www.ncbi.nlm.nih.gov/pubmed/28212573
http://dx.doi.org/10.18632/oncotarget.15338

Ejemplares similares